10.11.2022 - - Topline data from Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency on track for the fourth quarter of 2022 – - Topline data from Phase 1/2 clinical trial of INZ-701 in ABCC6 Deficiency on track for the first quarter of 2023 – .
Inozyme Pharma to Participate in Upcoming Investor Conferences streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Building a Pipeline of Therapies to Treat Rare Mineralization Disorders globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.
BOSTON, Sept. 06, 2022 Inozyme Pharma, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte,. | September 6, 2022
15.08.2022 - - Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency – - Appointed Kurt Gunter, M.D. as senior vice president and chief medical officer - - .